Merck & Co Says New Study Shows Alzheimer’s Drug Potential

Merck & Company said late Wednesday that new research into Verubecestat for the treatment of Alzheimer’s showed that the drug holds potential as a modifying therapy.

“We believe this research has the potential to contribute important evidence regarding the amyloid hypothesis, a leading scientific theory for what causes Alzheimer’s disease, and we look forward to seeing the data from our ongoing Phase 3 clinical trials,” said Michael Egan, VP of clinical development neurosciences at Merck Research Laboratories. “We believe this research has the potential to contribute important evidence regarding the amyloid hypothesis, a leading scientific theory for what causes Alzheimer’s disease, and we look forward to seeing the data from our ongoing Phase 3 clinical trials.”

The drug’s efficacy and safety of verubecestat is currently being evaluated in two pivotal phase 3 clinical trials, for the treatment of mild-to-moderate AD and prodromal AD, respectively.

Leave a Comment